Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Faricimab versus Aflibercept in Diabetic Macular Edema
2017-005105-12Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2018
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of faricimab in diabetic macular edema (DME) and diabetic retinopathy (DR) (2 arms), sponsored by Roche. Primary endpoint: Change from baseline in best-corrected visual acuity at 1 year. Started Sep 2018; status: completed.
02
Drugs
faricimab
03
Conditions
diabetic macular edema (DME)diabetic retinopathy (DR)
Beyond the preview
Go deeper on 2017-005105-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005105-12.